The global liver cancer therapeutics market is expected to grow at a CAGR of 5.5% from 2021 to 2030. The market is driven by the increasing incidence of liver cancer, which is mainly due to the rising prevalence of chronic hepatitis B and C infections. The increasing number of patients with chronic hepatitis B and C infection will lead to an increase in the number of patients with liver cancer, thereby driving the growth of this market during the forecast period.
The global liver cancer therapeutics market can be segmented on the basis of type into targeted therapy, radiation therapy, immunotherapy, and chemotherapy; on application into hepatocellular carcinoma (HCC), cholangio carcinoma (CC), hepatoblastoma (HB); and on region into North America, Latin America, Europe, Asia Pacific & Middle East & Africa.
-Liver cancer is the fifth most common cancer in the world, with an estimated 1.2 million new cases diagnosed each year.
-Liver cancer is a major cause of death worldwide, accounting for about one third of all cancers that are fatal.
-In the United States, liver cancer accounts for about 2% of all cancers and 3% of all deaths from cancer.
-The five year survival rate for patients with liver cancer varies depending on the stage at diagnosis: 5% to 10% for localized disease; 20% to 30% for regional disease; and less than 5% for metastatic disease.
Industry Growth Insights published a new data on “Liver Cancer Therapeutics Market”. The research report is titled “Liver Cancer Therapeutics Market research by Types (Targeted Therapy, Radiation Therapy, Immunotherapy, Chemotherapy, Other), By Applications (Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Other), By Players/Companies ArQule, Bayer, Bristol-Myers Squibb, Celsion, Eisai, Exelixis, Roche, Merck, Pfizer, IntegraGen”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Liver Cancer Therapeutics Market Research Report
By Type
Targeted Therapy, Radiation Therapy, Immunotherapy, Chemotherapy, Other
By Application
Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Other
By Companies
ArQule, Bayer, Bristol-Myers Squibb, Celsion, Eisai, Exelixis, Roche, Merck, Pfizer, IntegraGen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Liver Cancer Therapeutics Market Report Segments:
The global Liver Cancer Therapeutics market is segmented on the basis of:
Types
Targeted Therapy, Radiation Therapy, Immunotherapy, Chemotherapy, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ArQule
- Bayer
- Bristol-Myers Squibb
- Celsion
- Eisai
- Exelixis
- Roche
- Merck
- Pfizer
- IntegraGen
Highlights of The Liver Cancer Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Targeted Therapy
- Radiation Therapy
- Immunotherapy
- Chemotherapy
- Other
- By Application:
- Hepatocellular Carcinoma
- Cholangio Carcinoma
- Hepatoblastoma
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Liver Cancer Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Liver cancer therapeutics refers to the use of drugs and other treatments to treat liver cancer.
Some of the major players in the liver cancer therapeutics market are ArQule, Bayer, Bristol-Myers Squibb, Celsion, Eisai, Exelixis, Roche, Merck, Pfizer, IntegraGen.
The liver cancer therapeutics market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Liver Cancer Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Liver Cancer Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Liver Cancer Therapeutics Market - Supply Chain
4.5. Global Liver Cancer Therapeutics Market Forecast
4.5.1. Liver Cancer Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Liver Cancer Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Liver Cancer Therapeutics Market Absolute $ Opportunity
5. Global Liver Cancer Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Liver Cancer Therapeutics Market Size and Volume Forecast by Type
5.3.1. Targeted Therapy
5.3.2. Radiation Therapy
5.3.3. Immunotherapy
5.3.4. Chemotherapy
5.3.5. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Liver Cancer Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Liver Cancer Therapeutics Market Size and Volume Forecast by Application
6.3.1. Hepatocellular Carcinoma
6.3.2. Cholangio Carcinoma
6.3.3. Hepatoblastoma
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Liver Cancer Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Liver Cancer Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Liver Cancer Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Liver Cancer Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Liver Cancer Therapeutics Demand Share Forecast, 2019-2026
9. North America Liver Cancer Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Liver Cancer Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Liver Cancer Therapeutics Market Size and Volume Forecast by Application
9.4.1. Hepatocellular Carcinoma
9.4.2. Cholangio Carcinoma
9.4.3. Hepatoblastoma
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Liver Cancer Therapeutics Market Size and Volume Forecast by Type
9.7.1. Targeted Therapy
9.7.2. Radiation Therapy
9.7.3. Immunotherapy
9.7.4. Chemotherapy
9.7.5. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Liver Cancer Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Liver Cancer Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Liver Cancer Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Liver Cancer Therapeutics Market Size and Volume Forecast by Application
10.4.1. Hepatocellular Carcinoma
10.4.2. Cholangio Carcinoma
10.4.3. Hepatoblastoma
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Liver Cancer Therapeutics Market Size and Volume Forecast by Type
10.7.1. Targeted Therapy
10.7.2. Radiation Therapy
10.7.3. Immunotherapy
10.7.4. Chemotherapy
10.7.5. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Liver Cancer Therapeutics Demand Share Forecast, 2019-2026
11. Europe Liver Cancer Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Liver Cancer Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Liver Cancer Therapeutics Market Size and Volume Forecast by Application
11.4.1. Hepatocellular Carcinoma
11.4.2. Cholangio Carcinoma
11.4.3. Hepatoblastoma
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Liver Cancer Therapeutics Market Size and Volume Forecast by Type
11.7.1. Targeted Therapy
11.7.2. Radiation Therap
11.7.3. Immunotherapy
11.7.4. Chemotherapy
11.7.5. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Liver Cancer Therapeutics Demand Share, 2019-2026
12. Asia Pacific Liver Cancer Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Liver Cancer Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Liver Cancer Therapeutics Market Size and Volume Forecast by Application
12.4.1. Hepatocellular Carcinoma
12.4.2. Cholangio Carcinoma
12.4.3. Hepatoblastoma
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Liver Cancer Therapeutics Market Size and Volume Forecast by Type
12.7.1. Targeted Therapy
12.7.2. Radiation Therapy
12.7.3. Immunotherapy
12.7.4. Chemotherapy
12.7.5. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Liver Cancer Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Liver Cancer Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Liver Cancer Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Liver Cancer Therapeutics Market Size and Volume Forecast by Application
13.4.1. Hepatocellular Carcinoma
13.4.2. Cholangio Carcinoma
13.4.3. Hepatoblastoma
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Liver Cancer Therapeutics Market Size and Volume Forecast by Type
13.7.1. Targeted Therapy
13.7.2. Radiation Therapy
13.7.3. Immunotherapy
13.7.4. Chemotherapy
13.7.5. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Liver Cancer Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Liver Cancer Therapeutics Market: Market Share Analysis
14.2. Liver Cancer Therapeutics Distributors and Customers
14.3. Liver Cancer Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. ArQule
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bayer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bristol-Myers Squibb
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Celsion
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Eisai
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Exelixis
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Roche
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Merck
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Pfizer
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. IntegraGen
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
